Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sangamo Therapeutics filings document regulatory, clinical, financial and corporate-status disclosures for a genomic medicine company developing gene therapy and genome-engineering technologies. Recent 8-K reports cover operating and financial results, clinical data from the STAAR study of isaralgagene civaparvovec, or ST-920, regulatory-pathway disclosures for Fabry disease, and material-event updates tied to the company's neurology pipeline.
The filing record also includes Nasdaq listing-compliance and delisting notices, SGMO common-stock registration information, finance leadership and officer-transition disclosures, and capital-structure information. These documents formalize the company's reported results, governance changes, securities status and clinical-regulatory events under SEC reporting rules.
Sangamo Therapeutics, Inc. reported that its Audit Committee terminated Ernst & Young LLP as its independent registered public accounting firm on June 25, 2026, following the company’s previously announced voluntary Chapter 11 bankruptcy filing (Case No. 26-10989).
EY’s audit reports for the years ended December 31, 2024 and 2025 were unqualified but included an explanatory paragraph about Sangamo’s ability to continue as a going concern. The company states there were no disagreements or reportable events with EY through June 25, 2026 and has not yet engaged a new auditor.
Sangamo also noted that on June 24, 2026 its common stock began trading on the OTCID Basic Market under the symbol SGMOQ, while its Nasdaq Capital Market listing under SGMO remains in place during an ongoing appeal of a Nasdaq delisting determination.
Sangamo Therapeutics, Inc. filed Amendment No. 1 to a previously submitted current report to add two asset purchase agreements as exhibits. The amendment does not change any information previously disclosed in the original report covering Items 1.01, 1.03, 2.03 and 2.05.
The new exhibits are asset purchase agreements dated June 22, 2026, with counterparties including Eli Lilly and Company and Astellas Gene Therapies, Inc., along with certain Sangamo subsidiaries. The filing is administrative in nature and focused on completing the exhibit set.
Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection in Delaware and will operate as a debtor-in-possession while it seeks to maximize value through asset sales. The company is pursuing two stalking horse transactions: a $50 million sale of its gene-editing and capsid platforms and related rights to Eli Lilly, and a sale of its Fabry disease program to Astellas for $25 million upfront plus up to $25 million in milestones, each subject to higher bids and court approval.
Sangamo has arranged a debtor-in-possession credit facility of up to $30 million, with an initial draw of up to $10.5 million pending court approval, secured by first priority liens on substantially all assets. The board also approved a major restructuring that will eliminate approximately 51 U.S. roles, about 40% of its workforce, leaving around 77 employees and generating expected severance and benefits costs of $3.0–$4.0 million plus about $0.5 million of paid-time-off payouts.
Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, had 1,630 shares of Common Stock surrendered to the company on May 25, 2026 for mandatory tax withholding tied to a restricted stock unit (RSU) vesting. The withholding used the issuer’s closing stock price of $0.1743 per share and is classified as a disposition to the issuer for reporting purposes, not an open-market trade. After this tax-withholding transaction, Davis directly holds 113,654 shares. The footnotes state this includes 3,031 shares from the May 25, 2026 vesting installment of a February 25, 2025 RSU grant, with an additional 32,633 RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service under the 2018 equity incentive plan.
Sangamo Therapeutics’ Principal Accounting Officer, Nikunj Jain, reported a routine tax-withholding transaction tied to restricted stock unit (RSU) vesting. On May 25, 2026, 1,919 shares of common stock were surrendered to the company at $0.1743 per share to cover mandatory taxes.
This disposition was required under the company’s 2018 Equity Incentive Plan and was not an open-market trade. After this withholding, Jain directly holds 235,292 shares. The RSU grant that partially vested on this date delivered 2,742 shares, with 32,633 additional shares scheduled to vest in seven equal quarterly installments, subject to continued service.
Sangamo Therapeutics senior vice president and chief development officer Nathalie Dubois-Stringfellow reported a tax-related share disposition. She surrendered 4,036 shares of common stock at a value of $0.1743 per share to cover mandatory tax withholding on a restricted stock unit (RSU) vesting that occurred on May 25, 2026.
This transaction is classified as a required tax-withholding disposition to the company, not a discretionary open-market trade. After the withholding, she directly holds 328,733 shares of common stock. The vesting relates to a February 25, 2025 RSU grant under the company’s 2018 equity incentive plan.
Sangamo Therapeutics SVP Scott B. Willoughby reported a routine tax-withholding share disposition tied to restricted stock vesting. On May 25, 2026, 4,036 shares of common stock were surrendered to the company at $0.1743 per share solely to satisfy mandatory tax withholding on vested RSUs, not as an open-market trade. After this non-discretionary transaction, he directly holds 647,370 shares. A footnote notes that 7,214 shares vested from a February 25, 2025 RSU grant on the same date, with 78,750 additional RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service.
Sangamo Therapeutics CEO Sandy Macrae reported a tax-withholding disposition of 12,613 shares of Common Stock. These shares came from a restricted stock unit (RSU) grant vesting on May 25, 2026 and were surrendered to the company solely to cover mandatory taxes at $0.1743 per share.
The filing notes this is treated as a disposition to the issuer for reporting purposes but is not a discretionary open-market trade. After this transaction, Macrae holds 1,895,043 shares directly. The vesting event included 22,543 shares from a February 25, 2025 RSU grant, with 246,094 additional RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service.
Sangamo Therapeutics ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 40,400,067 shares of Sangamo Therapeutics Common Stock, representing 9.75% of the class. The filing states Armistice Capital serves as investment manager for the Master Fund and exercises shared voting and dispositive power over these shares.
Sangamo Therapeutics reports a first‑quarter 2026 net loss of $30,995 thousand on revenues of $1,442 thousand, down from $6,437 thousand a year earlier, as operating expenses remained high at $33,388 thousand.
Cash and cash equivalents were $27,586 thousand as of March 31, 2026, against total liabilities of $78,920 thousand and a stockholders’ deficit of $18,955 thousand.
The company raised $23,346 thousand through an underwritten equity and warrant offering and $3,732 thousand via its at‑the‑market program but still discloses substantial doubt about its ability to continue as a going concern without significant near‑term financing or partnering transactions.
Sangamo also received a Nasdaq delisting determination due to minimum bid price noncompliance; its common stock was suspended from Nasdaq trading on May 5, 2026 and began trading on the OTCQB Venture Market, while the company appeals the delisting.